What Has Been the Progress and Growth of the Medical Foods For Orphan Diseases Market in Recent Years?
The medical foods for orphan diseases market has seen considerable growth due to a variety of factors.
•The market size for medical foods catering to orphan diseases has seen significant growth in recent times. The market, which was valued at $1.33 billion in 2024, is projected to expand up to $1.42 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.0%.
Factors such as orphan drug designation, advancements in research and development, increased government aid and grants, regulatory procedures, and enhanced diagnostic techniques contributed to the growth during the historic period.
What Can Be Expected from the Medical Foods For Orphan Diseases Market in the Coming Years?
The medical foods for orphan diseases market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for medical foods for rare diseases is predicted to witness significant growth in the upcoming years, expanding to $1.82 billion by 2029 with a compound annual growth rate (CAGR) of 6.4%.
This progression throughout the forecast period can be credited to advancements such as telemedicine, remote patient monitoring, the integration of healthcare systems, the rise of new technologies in food science, and precision nutrition. Also, patient demand is rising. The period will be marked by key trends like long-term effectiveness research, diet formulations specific to diseases, educational and training initiatives, emphasis on gut microbiome, and the innovation of nutritional supplements.
What Main Forces Are Fueling Expansion In The Medical Foods For Orphan Diseases Market?
The medical foods for orphan diseases market is predicted to expand due to the increasing occurrences of orphan diseases. Often referred to as rare diseases, orphan diseases are medical conditions that impact a limited number of people within a demographic. These particular conditions are managed using medical foods to fulfill the specific nutritional requirements of affected individuals. Consequently, the growing instances of rare diseases bolster the market for medical foods designed for these specific conditions. For example, non-Hodgkin lymphoma, an orphan disease, was found to be one of the most prevalent types of cancer in the United States. In January 2023, the American Cancer Society, a health-focused nonprofit organization based in the United States, reported that this rare disease made up about 4% of 2023's cancer cases, with an estimated 80,550 new diagnoses. As a result, the increasing incidences of rare diseases are propelling the growth of the market for specially formulated medical foods.
What Are The Primary Segments In The Global Medical Foods For Orphan Diseases Market?
The medical foods for orphan diseases market covered in this report is segmented –
1) By Product: Pills, Powder, Liquid, Other Products
2) By Route Of Administration: Oral, Enteral
3) By Applications: Phenylketonuria, Tyrosinemia, Eosinophilic esophagitis, Food Protein-Induced Enterocolitis Syndrome (FPIES), Maple Syrup Urine Disease (MSUD), Homocystinuria, Other Applications
4) By Sales Channel: Online Sales, Institutional Sales, Retail Sales
Subsegments:
1) By Pills, Tablets, Capsules
2) By Powder: Protein Powders, Nutritional Supplement Powders
3) By Liquid: Ready-To-Drink Formulas, Liquid Nutritional Supplements
4) By Other Products: Nutritional Bars, Fortified Foods, Ready-To-Use Therapeutic Foods
Pre-Book The Medical Foods For Orphan Diseases Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Medical Foods For Orphan Diseases Market?
Trend 1: The emergence of product innovations is a prevalent trend observed in the market for medical foods for rare diseases. In order to secure their standing in the market, dominant companies are launching novel products. For example, Relief Therapeutics, a biopharmaceutical enterprise based in Switzerland, in October 2022, unveiled a revolutionary medical food product named PKU GOLIKE. This product, developed through their proprietary Physiomimic Technology platform, serves the dietary needs of individuals with phenylketonuria (PKU), which is an uncommon inherited disorder. With its unique coating, PKU GOLIKE is the inaugural prolonged-release amino acid product that ensures the physiological intake of amino acids while concealing their unappealing taste, smell, and aftertaste. This phenylalanine-free food, specifically designed for specialized medical needs (FSMP), is available in the United States.
Who Are the Key Players in the Medical Foods For Orphan Diseases Market?
Major companies operating in the medical foods for orphan diseases market include:
• Nestle S.A.
• Abbott Laboratories Inc.
• Danone S.A.
• Ajinomoto Co. Inc.
• Meiji Holdings Co. Ltd.
• Fresenius Kabi AG
• BioMarin Pharmaceutical Inc.
• Halyard Health
• Alfasigma spA
• Ultragenyx Pharmaceutical Inc.
• Immedica Group AB
• Vitaflo International Ltd.
• Leadiant Biosciences Inc.
• Alcresta Therapeutics Inc.
• Cambrooke Therapeutics Inc.
• Primus Pharmaceuticals Inc.
• CANbridge Pharmaceuticals Inc.
• Cerecin Inc.
• AMNIOX Medical Inc.
• Targeted Medical Pharma Inc.
• Solace Nutrition LLC
• Orphan Therapeutics LLC
• Metagenics Inc.
• Farma Genetics Inc.
What Is The Most Dominant Region In The Medical Foods For Orphan Diseases Market?
North America was the largest region in the medical foods for orphan diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical foods for orphan diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
